CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 146 filers reported holding CATALYST PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.54 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $563,855 | -12.2% | 48,234 | +1.0% | 0.00% | -100.0% |
Q2 2023 | $642,123 | -30.4% | 47,777 | -14.2% | 0.00% | 0.0% |
Q1 2023 | $923,241 | +17.3% | 55,684 | +31.6% | 0.00% | 0.0% |
Q4 2022 | $787,022 | +109.9% | 42,313 | +44.9% | 0.00% | – |
Q3 2022 | $375,000 | +140.4% | 29,200 | +30.8% | 0.00% | – |
Q2 2022 | $156,000 | +300.0% | 22,324 | +90.4% | 0.00% | – |
Q4 2020 | $39,000 | +11.4% | 11,726 | 0.0% | 0.00% | – |
Q3 2020 | $35,000 | -57.3% | 11,726 | -33.8% | 0.00% | – |
Q2 2020 | $82,000 | +13.9% | 17,726 | -5.3% | 0.00% | – |
Q1 2020 | $72,000 | -29.4% | 18,726 | -31.0% | 0.00% | – |
Q4 2019 | $102,000 | -16.4% | 27,133 | +17.9% | 0.00% | – |
Q3 2019 | $122,000 | +82.1% | 23,007 | +31.4% | 0.00% | – |
Q2 2019 | $67,000 | +1.5% | 17,507 | +34.6% | 0.00% | – |
Q1 2019 | $66,000 | +127.6% | 13,007 | -13.3% | 0.00% | – |
Q4 2018 | $29,000 | -38.3% | 15,007 | +20.0% | 0.00% | – |
Q3 2018 | $47,000 | – | 12,507 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANAKA CAPITAL MANAGEMENT INC | 148,281 | $2,458 | 7.14% |
GABLES CAPITAL MANAGEMENT INC. | 409,080 | $6,782,546 | 4.74% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 10,355,099 | $171,687,541 | 3.83% |
JW Asset Management, LLC | 563,392 | $9,341,039 | 3.58% |
Quantedge Capital Pte Ltd | 324,700 | $5,383,526 | 2.10% |
Paradiem, LLC | 236,628 | $3,923,292 | 1.22% |
SummerHaven Investment Management, LLC | 100,592 | $1,667,815 | 0.97% |
Capital Impact Advisors, LLC | 46,096 | $764,272 | 0.94% |
Yorktown Management & Research Co Inc | 50,000 | $829,000 | 0.89% |
Seaport Global Advisors, LLC | 15,598 | $258,615 | 0.82% |